SCHEMBL2962273

SCHEMBL2962273

O=C(Cl)N1CCc2sccc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.50
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
SLC6A4 P31645 2/20 0.43
SLC6A2 P23975 1/20 0.43
AKR1C3 P42330 1/20 0.43
ABCB11 O95342 3/20 0.42
CYP2C19 P33261 3/20 0.42
ADRA2A P08913 2/20 0.42
CYP2B6 P20813 2/20 0.42
DRD1 P21728 2/20 0.42
OPRM1 P35372 2/20 0.42
OPRK1 P41145 2/20 0.42
HTR2B P41595 2/20 0.42
KCNH2 Q12809 2/20 0.42
THRB P10828 1/20 0.42
NR1I2 O75469 1/20 0.42
CHRM2 P08172 1/20 0.42
HTR2A P28223 1/20 0.42
P2RY12 Q9H244 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023735 0.84 HSP90AA1 (0.51) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL8680487 0.83 NOTUM (0.57) HSP90AA1PRMT5WDR77SLC6A4AKR1C3
SCHEMBL19722818 0.83 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL4253684 0.83 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL22481607 0.82 HSP90AA1 (0.47) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL31514479 0.79 ESR1 (0.55) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL21411295 0.79 KEAP1 (0.52) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL16219051 0.79 HSP90AA1 (0.56) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL19296215 0.79 HSP90AA1 (0.50) HSP90AA1PRMT5WDR77SLC6A4SLC6A2
SCHEMBL31166136 0.78 PRMT5 (0.53) HSP90AA1PRMT5WDR77SLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357698-B2 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2013-01-22 US disclosed
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2010-11-11 US disclosed
US-7772268-B2 inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL HSP90AA1 3386/4885PRMT5 1193/4885WDR77 3480/4885
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL HSP90AA1 3386/4885PRMT5 1193/4885WDR77 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.